CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CLD HEALTH OUTCOMES
CIRRHOSIS
CIRRHOSIS HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS)
NASH
CHOLESTATIC
PRIMARY BILIARY CHOLANGITIS (PBC)
HCC ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
About CLDF
Board of Trustees Embassy of Education CLDF Committees 2023 GI Fellow Board of Advisors
Embassy of Education
Publications Webcasts Abstract Library Committee Members
 
NASH Single Disease Content  
Publications
 
Slide Library
   Released: 2023
test
NASH PATHway to Treatment
Michael Charlton, MD
Rohit Loomba, MD
Maru E. Rinella, MD
97 slides
 
 
   Released: 2023
test
Advances in NAFLD/NASH
Kris V. Kowdley, MD
55 slides
 
 
   Released: 2022
test
 
   Released: 2022
test
 
   Released: 2022
test
Pearls and Pitfalls: Update on emerging therapies in NASH
Michael Charlton, MD & Rohit Loomba, MD
97 slides
 
 
   Released: 2021
test
The Puzzle in Hepatorenal Syndrome Management
Hugo E. Vargas, MD
40 slides
 
 
   Released: 2021
test
COVID-19 and Managing Liver Disease
K. Rajender Reddy, M.D.
33 slides
 
 
   Released: 2021
test
Alcohol-Associated Liver Disease
Michael R. Lucey MD
43 slides
 
 
   Released: 2021
test
Chronic Hepatitis B and D: Emerging Concepts and Treatment
Robert G Gish MD, FAASLD, AGAF, FAST
42 slides
 
 
   Released: 2021
test
Management of Refractory Hepatic Encephalopathy
Jasmohan S. Bajaj, MD
41 slides
 
 
   Released: 2021
test
Hepatitis C: Elimination Strategies in the US
David Bernstein, MD, FAASLD, FACG, FACP, AGAF
43 slides
 
 
   Released: 2021
test
Management of Hepatocellular Carcinoma in 2021
Laura Kulik, MD
45 slides
 
 
   Released: 2021
test
Hot Topics In Pediatric Liver Disease
Rohit Kohli, MBBS, MS
35 slides
 
 
   Released: 2021
test
Thrombocytopenia in CLD
Robert S. Brown, Jr., MD, MPH
32 slides
 
 
   Released: 2021
test
Cholestatic Liver Disease: Current Management and Emerging Therapies
Kris V. Kowdley MD
36 slides
 
 
   Released: 2021
test
Emerging Therapies in NASH
Stephen A Harrison, MD, FACP, FAASLD
32 slides
 
 
   Released: 2021
test
Identifying High Risk NASH Patients Using Noninvasive Techniques (NITs)
Mazen Noureddin, MD, MHSc
42 slides
 
 
   Released: 2021
test
Burden of NASH: Why Do We Need to Care?
21 slides
 
 
   Released: 2021
test
NASH Screening and Diagnosis in Primary Care and Endocrinology Practice Settings: The Role of NITs
52 slides
 
 
   Released: 2021
test
NASH Screening and Diagnosis in Specialty Clinics: The Role of Radiologic Modalities, Serum Fibrosis Tests and Algorithm
40 slides
 
 
   Released: 2021
test
Treatment Endpoints: Clinical vs Regulatory Endpoints
39 slides
 
 
   Released: 2021
test
Combination Therapies in NASH: What's Promising?
21 slides
 
 
   Released: 2021
test
Lifestyle Modification and Current Treatment Regimens for NAFLD
29 slides
 
 
   Released: 2021
test
New Targets for Emerging Therapies in NASH
26 slides
 
 
   Released: 2020
test
Imaging as an Outcome and Endpoint for Clinical Trials of NASH
29 slides
 
 
   Released: 2020
test
Clinical Management of NASH: Diet and Nutrition
41 slides
 
 
   Released: 2020
test
The Comprehensive Global Burden and Impact of NASH
32 slides
 
 
   Released: 2020
test
NAFLD and Cardiovascular Disease
43 slides
 
 
   Released: 2020
test
Imaging as an Outcome and Endpoint for Clinical Trials of NASH
29 slides
 
 
   Released: 2020
test
Challenges in Management and Clinical Trials of NASH in Children
26 slides
 
 
   Released: 2020
test
Weight Loss in NASH: Role of Weight Loss Medications and Surgery
17 slides
 
 
   Released: 2020
test
Why NASH and Exercise?
43 slides
 
 
   Released: 2020
test
Is Histologic Fibrosis Assessment an Appropriate Endpoint / Reference Standard for Clinical Trials?
25 slides
 
 
   Released: 2020
test
NASH and Diabetes Linkage: Where do we go from here?
42 slides
 
 
   Released: 2020
test
Serum Biomarkers and Clinical Algorithms in NASH: Utility in Clinical Trials and Clinical Practice
49 slides
 
 
   Released: 2020
test
Best Practices in NASH Management and Current Status of Drug Development
37 slides
 
 
   Released: 2020
test
Imaging as an Outcome and Endpoint for Clinical Trials of NASH
35 slides
 
 
   Released: 2020
test
NASH: Current Approach and When Will New Treatment Options Be Available?
39 slides
 
 
   Released: 2018
Webcast
NASH 2018
61 slides
 
 
   Released: 2016
Webcast
Get Ready for the Global Epidemic of NASH: Evolving Diagnosis and Treatment Strategies
66 slides
 
 
   Released: 2015
Webcast
Best of the Liver Summit: PBC, NAFLD/NASH and HCV
78 slides
 
 
   Released: 2015
Webcast
Hepatology Update: New Developments in PBC, NAFLD & NASH
77 slides
 
 
   Released: 2015
Webcast
THE LIVER SUMMIT
89 slides
 
 
 
 
Webcast Library
CLDF Conversations: New Therapies in MASH & Comprehensive Care
Hosted by Nadege Gunn, MD, with Special Guest Sujit Janardhan, MD, PhD 		  Educational Webcast
Expert Perspectives Post Conference Highlights on MASLD/MASH from DDW
Rohit Loomba, MD, MHSc, Nadege T. Gunn, MD, CPI, and HoChong Gilles, DNP, FNP-BC 		  Accredited Webcast
Metabolic-Associated Steatotic Liver Disease: Positioning New and Emerging Therapies with Nancy Reau, MD, Kimberly Brown, MD, and Steven Flamm, MD.   Educational Webcast
Key Take Aways-Major Advancements In The Management of MASH with Parvez, Mantry, MD   Educational Webcast
Major Advancement in MASH Management
Presented by the MASH Alliance at the 2024 IU GI & Hepatology Update Conference 		  Symposium Vignettes
Major Advancement in MASH Management
Presented by the MASH Alliance at the 2024 Liver Connect Conference 		  Symposium Vignettes
Major Advancement in MASH Management
Presented by the MASH Alliance at the 2024 GALA Dallas Conference 		  Symposium Vignettes
Major Advancement in MASH Management
Presented by the MASH Alliance at the 2024 Advancing GI Patient Care Conference 		  Symposium Vignettes
Liver Connect 2023   Educational Webcast
NASH Connect 2023   Educational Webcast
NAFLD/NASH   Educational Webcast
Advances in NAFLD/NASH   Educational Webcast
New Advances in NASH Diagnostics and Prognostics   Educational Webcast
New Advances in NASH Diagnostics and Prognostics   Educational Webcast
Pearls and Pitfalls update on emerging therapies in NASH   Educational Webcast
Abstract Library
1.The cost implications of Wilson disease among hospitalized patients: analysis of USA hospitals
 

Eur JGastroenterolHepatol. 2024Jul1;36(7):929940. doi:10.1097/MEG.0000000000002777.Epub 2024 Apr 23.

 

David Uihwan Lee 1, Ashton Harmacinski 1, Aneesh Bahadur 2, Ki Jung Lee 2, Hannah Chou 2, Mohammed Rifat Shaik 1, Harrison Chou 2, Gregory Hongyuan Fan 2, Jean Kwon 2, Reid Ponder 2, Kevin Chang 2, KeeSeok Lee 2, Zurabi Lominadze 1
 
2.Emerging targets for therapy in ALD: Lessons from NASH
 

Hepatology. 2024 Jul 1;80(1):223-237. doi: 10.1097/HEP.0000000000000381.Epub 2023 Mar 21.

 

Ashwani K Singal 1 2 3, Vijay H Shah 4, Harmeet Malhi 4
 
3.How effective are experienced hepatologists at staging fibrosis using non-invasive fibrosis tests in patients with metabolic dysfunction-associated steatotic liver disease?
 

Aliment Pharmacol Ther. 2024 Jul;60(2):267-273. doi: 10.1111/apt.18061. Epub 2024 Jun 11.

 

Stuart McPherson 1 2 3, Jessica K Dyson 1 2 3, Laura Jopson 1, Steven Masson 1 2 3, Preya Patel 1, Quentin M Anstee 1 2 3
 
4.Hepatic fatty acid and glucose handling in metabolic disease: Potential impact on cardiovascular disease risk
 

Atherosclerosis. 2024 Jul:394:117237. doi: 10.1016/j.atherosclerosis.2023.117237.Epub 2023 Aug 11.

 

Felix Westcott 1, David J Dearlove 1, Leanne Hodson 2
 
5.Resmetirom: The First Food and Drug Administration-Approved Medication for Nonalcoholic Steatohepatitis (NASH)
 

Ann Pharmacother. 2024 Jun 17:10600280241259528.doi: 10.1177/10600280241259528. Online ahead of print.

 

Erenie Guirguis 1, John Dougherty 1, Krisy Thornby 1, Yasmin Grace 1, Keri Mack 1
 
6.A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease
 

Hepatol Int. 2024 Jun 15. doi: 10.1007/s12072-024-10702-5. Online ahead of print.

 

Huai Zhang 1, Giovanni Targher 2, Christopher D Byrne 3, Seung Up Kim 4, Vincent Wai-Sun Wong 5, Luca Valenti 6 7, Myer Glickman 8, Jaime Ponce 9, Christos S Mantzoros 10, Javier Crespo 11, Henning Gronbaek 12, Wah Yang 13, Mohammed Eslam 14, Robert J Wong 15, Mariana Verdelho Machado 16, Ming-Lung Yu 17 18, Omar M Ghanem 19, Takeshi Okanoue 20, Jun-Feng Liu 21, Yong-Ho Lee 22, Xiao-Yuan Xu 23, Qiuwei Pan 24, Meili Sui 25, Amedeo Lonardo 26, Yusuf Yilmaz 27, Li-Yong Zhu 28, Christophe Moreno 29, Luca Miele 30, Monica Lupsor-Platon 31, Lei Zhao 32, Teresa LeAnn LaMasters 33, Robert G Gish 34, Huijie Zhang 35, Marius Nedelcu 36, Wah Kheong Chan 37, Ming-Feng Xia 38, Fernando Bril 39, Jun-Ping Shi 40, Christian Datz 41, Stefano Romeo 42 43 44, Jian Sun 45, Dan Liu 46, Silvia Sookoian 47 48 49, Yi-Min Mao 50, Nahum Méndez-Sánchez 51, Xiao-Yan Wang 52, Nikolaos T Pyrsopoulos 53, Jian-Gao Fan 54, Yasser Fouad 55, Dan-Qin Sun 56 57, Cosimo Giannini 58, Jin Chai 59, Ze-Feng Xia 60, Dae Won Jun 61, Guo-Jing Li 62, Sombat Treeprasertsuk 63, Ying-Xu Li 
 
7.Association of physical activity and sports participation with insulin resistance and non-alcoholic fatty liver disease in people with type 1 diabetes
 

Diabet Med. 2024 Jul;41(7):e15317. doi: 10.1111/dme.15317. Epub 2024 Apr 8.

 

M de Vries 1, J Westerink 2, H A H Kaasjager 1, H W de Valk 1; UCC-SMART Study Group
 
8.Risk of adverse events in anticoagulated patients with atrial fibrillation and non-alcoholic fatty liver disease
 

J Clin Endocrinol Metab. 2024 Jun 12:dgae394. doi: 10.1210/clinem/dgae394.Online ahead of print.

 

Tommaso Bucci 1 2, Katarzyna Nabrdalik 1 3, Francesco Baratta 2, Daniele Pastori 2, Pasquale Pignatelli 2, Theresa Hydes 1 4, Uazman Alam 1 4, Francesco Violi 2, Gregory Y H Lip 1 5
 
9.Steatotic liver disease-associated all-cause/cause-specific mortality in the United States
 

Aliment Pharmacol Ther. 2024 Jul;60(1):33-42. doi: 10.1111/apt.18011. Epub 2024 Apr 22.

 

Donghee Kim 1, Karn Wijarnpreecha 2 3, George Cholankeril 4 5, Aijaz Ahmed 1
 
10.Review of current and new drugs for the treatment of metabolic-associated fatty liver disease
 

Hepatol Int. 2024 Jun 8. doi: 10.1007/s12072-024-10698-y. Online ahead of print.

 

Robert Gish 1, Jian-Gao Fan 2, Zahra Dossaji 3, Jeanne Fichez 4 5, Tooba Laeeq 6, Magnus Chun 6, Jerome Boursier 4 5
 
11.The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis
 

Diabetes Obes Metab. 2024 Jun;26(6):2001-2016. doi: 10.1111/dom.15524.Epub 2024 Mar 21.

 

Manal F Abdelmalek 1, Stephen A Harrison 2, Arun J Sanyal 3
 
12.Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study
 

BMC Med. 2024 Jun 3;22(1):221. doi: 10.1186/s12916-024-03366-3.

 

Ana-Lucia Mayén 1, Mirna Sabra 1, Elom K Aglago 2, Gabriel Perlemuter 3 4 5, Cosmin Voican 3 4 5, Ines Ramos 1, Charlotte Debras 1, Jessica Blanco 1, Vivian Viallon 1, Pietro Ferrari 1, Anja Olsen 6 7, Anne Tjønneland 6 7, Fie Langmann 7, Christina C Dahm 7, Joseph Rothwell 8, Nasser Laouali 8, Chloé Marques 8, Matthias B Schulze 9, Verena Katzke 10, Rudolf Kaaks 10, Domenico Palli 11, Alessandra Macciotta 12, Salvatore Panico 13, Rosario Tumino 14, Claudia Agnoli 15, Marta Farràs 16, Esther Molina-Montes 17 18 19 20, Pilar Amiano 18 21 22, María-Dolores Chirlaque 18 23, Jesús Castilla 18 24, Mårten Werner 25, Stina Bodén 26, Alicia K Heath 2, Kostas Tsilidis 2, Dagfinn Aune 2 27 28, Elisabete Weiderpass 29, Heinz Freisling 1, Marc J Gunter 2, Mazda Jenab 30
 
13.Surveillance of the liver in type 2 diabetes: important but unfeasible?
 

Diabetologia. 2024 Jun;67(6):961-973. doi: 10.1007/s00125-024-06087-7.Epub 2024 Feb 9.

 

Sami Qadri # 1 2, Hannele Yki-Järvinen # 3 4
 
14.FIB-4 as a screening and disease monitoring method in pre-fibrotic stages of metabolic dysfunction-associated fatty liver disease (MASLD)
 

JDiabetesComplications. 2024May21;38(7):108777. doi:10.1016/j.jdiacomp.2024.108777.Online ahead of print.

 

Stewart G Albert 1, Emily M Wood 2
 
15.Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020
 

Clin Gastroenterol Hepatol. 2024 Jun;22(6):1330-1332.e4. doi: 10.1016/j.cgh.2023.11.003.Epub 2023 Nov 8.

 

Markos Kalligeros 1, Athanasios Vassilopoulos 1, Stephanos Vassilopoulos 1, David W Victor 2, Eleftherios Mylonakis 3, Mazen Noureddin 4
 
16.Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies
 

Aliment Pharmacol Ther. 2024 Jun:59 Suppl 1:S1-S9. doi: 10.1111/apt.17833.

 

Pegah Golabi 1 2 3, Soroor Owrangi 1, Zobair M Younossi 1 2 3
 
17.Disparate outcomes in Hispanic patients with metabolic dysfunction-associated steatotic liver disease/steatohepatitis and type 2 diabetes: Large cohort study
 

World J Diabetes. 2024 May 15;15(5):886-897. doi: 10.4239/wjd.v15.i5.886.

 

Joseph Matthew Gosnell 1, George Golovko 2, Esteban Arroyave 3, Akshata Moghe 4, Michael L Kueht 5, Omar Abdul Saldarriaga 6, Kevin H McKinney 7, Heather L Stevenson 3, Monique R Ferguson 7
 
18.A prospective study on the prevalence of at-risk MASH in patients with type 2 diabetes mellitus in the United States
 

Aliment Pharmacol Ther. 2024 Jun;59(12):1571-1578. doi: 10.1111/apt.17997. Epub 2024 Apr 8.

 

Nikita Mittal 1, Harris Siddiqi 1, Egbert Madamba 1, Lisa Richards 1, Ricki Bettencourt 1, Veeral Ajmera 1 2, Rohit Loomba 1 2 3
 
19.Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures
 

Aliment Pharmacol Ther. 2024 May 20. doi: 10.1111/apt.18042. Online ahead of print.

 

Raj Vuppalanchi 1, Rohit Loomba 2, Arun J Sanyal 3, Amir Nikooie 4, Yuanyuan Tang 4, Deborah A Robins 4, Bram Brouwers 4, Mark L Hartman 4
 
20.Resmetirom: First Approval
 

Drugs. 2024 May 21. doi: 10.1007/s40265-024-02045-0. Online ahead of print.

 

Susan J Keam 1
 
21.Impact of GLP-1 Receptor Agonist Use in Patients With Steatotic Liver Disease and Type 2 Diabetes: A Retrospective Cohort Study
 

J Pharm Pract. 2024 May 8:8971900241253661. doi: 10.1177/08971900241253661.Online ahead of print.

 

Marci Wood 1, Amanda G Kennedy 2, Sidra Khan 1, Juvena R Hitt 2, Kayla Davis 3, Sheela S Reddy 4, Matthew P Gilbert 5
 
22.Age, BMI, and Type 2 Diabetes Modify the Relationship Between PNPLA3 and Advanced Fibrosis in Children and Adults With NAFLD
 

Clin Gastroenterol Hepatol. 2024 May;22(5):1024-1036.e2. doi:10.1016/j.cgh.2023.12.009.Epub 2023 Dec 23.

 

Chaowapong Jarasvaraparn 1, Eduardo Vilar-Gomez 2, Katherine P Yates 3, Laura A Wilson 3, Brent Neuschwander-Tetri 4, Rohit Loomba 5, Oscar Cummings 6, Miriam Vos 7, Stavra Xanthakos 8, Jeffrey Schwimmer 9, Jean P Molleston 1, Arun Sanyal 10, James Tonascia 11, Naga Chalasani 12
 
23.Liver fibrosis assessed via non-invasive tests is associated with incident heart failure in a general population cohort
 

ClinGastroenterolHepatol. 2024May7:S15423565(24)004087.doi:10.1016/j.cgh.2024.03.045. Online ahead of print.

 

Theresa J Hydes 1, Oliver J Kennedy 2, Kate Glyn-Owen 3, Ryan Buchanan 4, Julie Parkes 5, Daniel J Cuthbertson 6, Paul Roderick 7, Christopher D Byrne 8
 
24.Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction-associated steatohepatitis
 

Hepatol Commun. 2024 May 10;8(6):e0423. doi: 10.1097/HC9.0000000000000423.eCollection 2024 Jun 1.

 

Zobair M Younossi 1 2, Kamal Kant Mangla 3, Tina Landsvig Berentzen 3, Katrine Grau 3, Mette Skalshøi Kjær 3, Steen Ladelund 3, Louise Maymann Nitze 3, Crystal Coolbaugh 4, Chih-Yuan Hsu 4, Hannes Hagström 5 6
 
25.Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study
 

Hepatology. 2024 Jun 1;79(6):1401-1411. doi: 10.1097/HEP.0000000000000712.Epub 2023 Dec 12.

 

Arvid Engström 1, Viktor Wintzell 1, Mads Melbye 2 3 4 5, Henrik Svanström 1 6, Björn Eliasson 7, Soffia Gudbjörnsdottir 7 8, Kristian Hveem 4 9, Christian Jonasson 4 9, Anders Hviid 6 10, Peter Ueda 1, Björn Pasternak 1 6
 
View More
 
 

HEPATITIS

HBV
HCV
HDV

CLD HEALTH OUTCOMES

CIRRHOSIS

Cirrhosis
HE
HRS
Thrombocytopenia

NASH

Slide Library
Publications
Webcasts
Abstract Library Committee Members

CHOLESTATIC

PBC

HCC

Slide Library
Publications
Webcasts
Algorithm
Abstract Library Committee Members

ALCOHOL LIVER DISEASE

Recorded Educational Webinar

PEDIATRIC LIVER DISEASE

Webcasts
Slide Library
Abstract Library

About CLDF

Board of Trustees
Board of Advisors/Faculty
CLDF Committees
2024 GI Fellow Board of Advisors

Other Resources

Journal Abstracts

Subscribe

Be the first to know about our latest upcoming programs and events!
CLDF

Follow us
Facebook
Twitter
Youtube
LiverQ
The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2024 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.